Trinity Biotech Plc Stock Analysis

TRIB Stock  USD 0.74  0.01  1.37%   
Trinity Biotech plc is undervalued with Real Value of 2.27 and Target Price of 7.0. The main objective of Trinity Biotech stock analysis is to determine its intrinsic value, which is an estimate of what Trinity Biotech plc is worth, separate from its market price. There are two main types of Trinity Biotech's stock analysis: fundamental analysis and technical analysis.
The Trinity Biotech stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Trinity Biotech's ongoing operational relationships across important fundamental and technical indicators.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

Trinity Stock Analysis Notes

About 12.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings To Growth (PEG) ratio of 1.3. Trinity Biotech plc recorded a loss per share of 1.8. The entity last dividend was issued on the 5th of June 2015. The firm had 1:5 split on the 23rd of February 2024. Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market in the Americas, Africa, Asia, and Europe. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland. Trinity Bio operates under Pharmaceuticals And Biosciences classification in the United States and is traded on NASDAQ Exchange. It employs 477 people. To find out more about Trinity Biotech plc contact Aris Kekedjian at 353 1 276 9800 or learn more at https://www.trinitybiotech.com.

Trinity Biotech Quarterly Total Revenue

15.86 Million

Trinity Biotech plc Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Trinity Biotech's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Trinity Biotech plc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Trinity Biotech plc is way too risky over 90 days horizon
Trinity Biotech plc has some characteristics of a very speculative penny stock
Trinity Biotech plc appears to be risky and price may revert if volatility continues
Trinity Biotech plc has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 61.55 M. Net Loss for the year was (31.79 M) with profit before overhead, payroll, taxes, and interest of 21.44 M.
Trinity Biotech plc currently holds about 10.01 M in cash with (4.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41.
Trinity Biotech plc has a poor financial position based on the latest SEC disclosures
Roughly 12.0% of the company outstanding shares are owned by corporate insiders
Latest headline from bbc.co.uk: Tray Lolesio Wakefield Trinity sign Radcliffe Dolphins prop on two-year deal

Trinity Biotech plc Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Trinity Biotech previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
28th of March 2024
Upcoming Quarterly Report
View
4th of July 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Trinity Largest EPS Surprises

Earnings surprises can significantly impact Trinity Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2018-10-23
2018-09-300.060.05-0.0116 
2018-07-19
2018-06-300.060.070.0116 
2018-03-07
2017-12-310.070.080.0114 
View All Earnings Estimates

Trinity Stock Institutional Investors

Shares
Two Sigma Investments Llc2025-03-31
15.1 K
Integrys Wealth Advisors Llc2025-06-30
10 K
Advisor Group Holdings, Inc.2025-03-31
4.5 K
Morgan Stanley - Brokerage Accounts2025-03-31
2.2 K
Rhumbline Advisers2025-03-31
1.3 K
Jones Financial Companies Lllp2025-03-31
468
Atlantic Trust Group, Llc2025-03-31
222
Simplex Trading, Llc2025-03-31
215
Bank Of America Corp2025-03-31
40.0
Hunter Associates Inc.2025-03-31
375.1 K
Whitefort Capital Management, Lp.2025-03-31
81.9 K
Note, although Trinity Biotech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Trinity Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.61 M.

Trinity Profitablity

The company has Profit Margin (PM) of (0.52) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.43) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.43.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.61)(0.58)
Return On Capital Employed(0.30)(0.28)
Return On Assets(0.31)(0.29)
Return On Equity 0.90  0.95 

Management Efficiency

Trinity Biotech plc has return on total asset (ROA) of (0.1053) % which means that it has lost $0.1053 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.1345) %, meaning that it created substantial loss on money invested by shareholders. Trinity Biotech's management efficiency ratios could be used to measure how well Trinity Biotech manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.95, whereas Return On Tangible Assets are projected to grow to (0.58). At present, Trinity Biotech's Total Assets are projected to decrease significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 72.7 M, whereas Non Currrent Assets Other are forecasted to decline to about 184.3 K.
Last ReportedProjected for Next Year
Book Value Per Share(0.10)(0.09)
Tangible Book Value Per Share(0.24)(0.23)
Enterprise Value Over EBITDA(24.36)(25.58)
Price Book Value Ratio(0.45)(0.43)
Enterprise Value Multiple(6.59)(6.26)
Price Fair Value(0.45)(0.43)
Enterprise Value473.5 M449.8 M
The operational strategies employed by Trinity Biotech management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Operating Margin
(0.43)
Profit Margin
(0.52)
Beta
0.81
Return On Assets
(0.11)
Return On Equity
(19.13)

Technical Drivers

As of the 21st of July, Trinity Biotech has the Coefficient Of Variation of 1148.32, risk adjusted performance of 0.0897, and Semi Deviation of 3.99. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Trinity Biotech plc, as well as the relationship between them.

Trinity Biotech plc Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Trinity Biotech for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Trinity Biotech plc short-term fluctuations and highlight longer-term trends or cycles.

Trinity Biotech Outstanding Bonds

Trinity Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Trinity Biotech plc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Trinity bonds can be classified according to their maturity, which is the date when Trinity Biotech plc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Trinity Biotech Predictive Daily Indicators

Trinity Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Trinity Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Trinity Biotech Forecast Models

Trinity Biotech's time-series forecasting models are one of many Trinity Biotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Trinity Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Trinity Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Trinity Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Trinity shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Trinity Biotech. By using and applying Trinity Stock analysis, traders can create a robust methodology for identifying Trinity entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.50)(0.47)
Operating Profit Margin(0.34)(0.33)
Net Loss(0.52)(0.49)
Gross Profit Margin 0.35  0.33 

Current Trinity Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Trinity analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Trinity analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
7.0Strong Buy1Odds
Trinity Biotech plc current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Trinity analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Trinity stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Trinity Biotech plc, talking to its executives and customers, or listening to Trinity conference calls.
Trinity Analyst Advice Details

Trinity Stock Analysis Indicators

Trinity Biotech plc stock analysis indicators help investors evaluate how Trinity Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Trinity Biotech shares will generate the highest return on investment. By understating and applying Trinity Biotech stock analysis, traders can identify Trinity Biotech position entry and exit signals to maximize returns.
Begin Period Cash Flow3.7 M
Long Term Debt87.8 M
Common Stock Shares Outstanding18 M
Total Stockholder Equity-35.2 M
Total Cashflows From Investing Activities-23 M
Tax Provision486 K
Quarterly Earnings Growth Y O Y-0.773
Property Plant And Equipment Net4.6 M
Cash And Short Term Investments5.2 M
Cash5.2 M
Accounts Payable6.8 M
Net Debt95.6 M
50 Day M A0.7032
Total Current Liabilities32.1 M
Other Operating Expenses82.7 M
Non Current Assets Total62.2 M
Non Currrent Assets Other194 K
Stock Based Compensation1.3 M

Complementary Tools for Trinity Stock analysis

When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity